152 related articles for article (PubMed ID: 2902114)
1. Effect of levocabastine, a new H1 antagonist, in a conjunctival provocation test with allergens.
Zuber P; Pécoud A
J Allergy Clin Immunol; 1988 Oct; 82(4):590-4. PubMed ID: 2902114
[TBL] [Abstract][Full Text] [Related]
2. Comparison of effects of topical levocabastine and nedocromil sodium on the early response in a conjunctival provocation test with allergen.
Hammann C; Kämmerer R; Gerber M; Spertini F
J Allergy Clin Immunol; 1996 Dec; 98(6 Pt 1):1045-50. PubMed ID: 8977503
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of three antiallergic eyedrops in a specific conjunctival provocation test: mequitazine, levocabastine and dexamethasone].
Richard C; Bibas P; Lablache-Combier M; Allaire C
J Fr Ophtalmol; 2005 Mar; 28(3):244-50. PubMed ID: 15883488
[TBL] [Abstract][Full Text] [Related]
4. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model.
Netland PA; Leahy C; Krenzer KL
Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model.
Friedlaender MH; Harris J; LaVallee N; Russell H; Shilstone J
Ophthalmology; 2000 Dec; 107(12):2152-7. PubMed ID: 11097587
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of levocabastine hydrochloride ophthalmic suspension in the conjunctival allergen challenge test in Japanese subjects with seasonal allergic conjunctivitis.
Takamura E; Nomura K; Fujishima H; Fukagawa K; Satake Y; Fukada Y; Sawa M; Uchida E
Allergol Int; 2006 Jun; 55(2):157-65. PubMed ID: 17075252
[TBL] [Abstract][Full Text] [Related]
7. Topical levocabastine protects better than sodium cromoglycate and placebo in conjunctival provocation tests.
Rimås M; Kjellman NI; Blychert LO; Björkstén B
Allergy; 1990 Jan; 45(1):18-21. PubMed ID: 1968726
[TBL] [Abstract][Full Text] [Related]
8. Effect of a new selective H1 receptor antagonist (levocabastine) in a nasal and conjunctival provocation test.
Pécoud A; Zuber P; Kolly M
Int Arch Allergy Appl Immunol; 1987; 82(3-4):541-3. PubMed ID: 2883132
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
Abelson MB; Greiner JV
Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
[TBL] [Abstract][Full Text] [Related]
10. [Safety and efficacy of a new preservative-free levocabastine ophthalmic solution (Levofree®) using the conjunctival provocation test].
Allaire C; Siou-Mermet R; Bassols A
J Fr Ophtalmol; 2012 Sep; 35(7):491-8. PubMed ID: 22498504
[TBL] [Abstract][Full Text] [Related]
11. Effect of cetirizine in a conjunctival provocation test with allergens.
Schoeneich M; Pécoud AR
Clin Exp Allergy; 1990 Mar; 20(2):171-4. PubMed ID: 1972648
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of mequitazine in comparison with placebo assessed by ocular challenge with allergen in allergic conjunctivitis.
Persi L; Dupin O; Arnaud B; Trinquand C; Michel FB; Bousquet J
Allergy; 1997 Apr; 52(4):451-4. PubMed ID: 9188930
[TBL] [Abstract][Full Text] [Related]
13. Randomised double masked trial comparing the efficacy and tolerance of 0.05% mequitazine eye drops versus 0.05% levocabastine and placebo in allergic conjunctivitis induced by a conjunctival provocation test with Dermatophagoides pteronyssinus.
Mortemousque B; Jacquet A; Richard C; Depont F; Colin J; Moore N
Br J Ophthalmol; 2004 Mar; 88(3):336-40. PubMed ID: 14977764
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of levocabastine in conjunctival provocation studies.
Janssens M
Doc Ophthalmol; 1992; 82(4):341-51. PubMed ID: 1363980
[TBL] [Abstract][Full Text] [Related]
15. Comparison of levocabastine, a new selective H1-receptor antagonist, and disodium cromoglycate, in a nasal provocation test with allergen.
Kolly M; Pécoud A
Br J Clin Pharmacol; 1986 Oct; 22(4):389-94. PubMed ID: 2876723
[TBL] [Abstract][Full Text] [Related]
16. The early efficacy of topical levocabastine in patients with allergic conjunctivitis.
Fujishima H; Fukagawa K; Takano Y; Okamoto S; Nakagawa Y; Uchio E; Yokoi N; Fukushima A; Takamura E
Allergol Int; 2006 Sep; 55(3):301-3. PubMed ID: 17075271
[TBL] [Abstract][Full Text] [Related]
17. New trends in the treatment of allergic conjunctivitis.
Parys W; Blockhuys S; Janssens M
Doc Ophthalmol; 1992; 82(4):353-60. PubMed ID: 1363981
[TBL] [Abstract][Full Text] [Related]
18. Effect of antihistamine eye drops on the conjunctival provocation test with Japanese cedar pollen allergen.
Dake Y; Enomoto T; Cheng L; Enomoto K; Shibano A; Ikeda H; Yoda S; Yajin S; Sakota T; Yamanishi E
Allergol Int; 2006 Dec; 55(4):373-8. PubMed ID: 17130679
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis.
Abelson MB; George MA; Schaefer K; Smith LM
J Allergy Clin Immunol; 1994 Sep; 94(3 Pt 1):458-64. PubMed ID: 7916020
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis.
Verin P; Easty DL; Secchi A; Ciprandi G; Partouche P; Nemeth-Wasmer G; Brancato R; Harrisberg CJ; Estivin-Ebrardt C; Coster DJ; Apel AJ; Coroneo MT; Knorr M; Carmichael TR; Kent-Smith BT; Abrantes P; Leonardi A; Cerqueti PM; Modorati G; Martinez M
Am J Ophthalmol; 2001 Jun; 131(6):691-8. PubMed ID: 11384563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
